Received Apr 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | M2RH3 | — |
27-year-old patient received a pediatric dose of Engerix-B; Underdose; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 27-year-old female patient who received HBV (Engerix B pediatric) (batch number M2RH3) for prophylaxis. On 04-APR-2025, the patient received the 1st dose of Engerix B pediatric. On 04-APR-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: 27-year-old patient received a pediatric dose of Engerix-B) and underdose (Verbatim: Underdose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 08-APR-2025 The registered nurse stated that a 27-year-old patient received a pediatric dose of Engerix-B, first dose, which led to adult use of a child product and underdose. No side effects or adverse reactions noted. The Vaccine Administration Facility is the same as Primary Reporter.